Atea Pharmaceuticals (AVIR) News Today $3.22 -0.09 (-2.72%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024November 15 at 11:00 AM | globenewswire.comBML Capital Management LLC Has $22.28 Million Stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)BML Capital Management LLC increased its stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 4.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,650,000 shares of the company's stock after pNovember 12, 2024 | marketbeat.comAtea Pharmaceuticals (AVIR) Gets a Hold from Morgan StanleyNovember 12, 2024 | markets.businessinsider.comAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q3 2024 Earnings Call TranscriptNovember 11, 2024 | msn.comAtea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business UpdateAtea Pharmaceuticals, Inc. (NASDAQ: AVIR) recently issued a press release detailing its financial results for the third quarter ending September 30, 2024, aNovember 10, 2024 | americanbankingnews.comAtea Pharmaceuticals, Inc. (AVIR) Q3 2024 Earnings Call TranscriptNovember 9, 2024 | seekingalpha.comAtea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 7, 2024 | globenewswire.comAtea Pharmaceuticals (AVIR) Scheduled to Post Quarterly Earnings on ThursdayAtea Pharmaceuticals (NASDAQ:AVIR) will be releasing earnings after the market closes on Thursday, November 7, Zacks reports.November 1, 2024 | marketbeat.comAtea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024October 30, 2024 | globenewswire.comDimensional Fund Advisors LP Buys 211,428 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)Dimensional Fund Advisors LP boosted its stake in shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 55.2% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 594,360 shares of the compaOctober 12, 2024 | marketbeat.com182,326 Shares in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Purchased by Marshall Wace LLPMarshall Wace LLP purchased a new position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 182,326 shares of the company's stockOctober 10, 2024 | marketbeat.comAtea Pharmaceuticals Inc (AVIR) Q2 2024 Earnings Call Highlights: Strong Financial Position and ...October 9, 2024 | finance.yahoo.comAtea Pharmaceuticals (NASDAQ:AVIR) Stock, Short Interest ReportOctober 7, 2024 | benzinga.comAlmitas Capital LLC Buys New Shares in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)Almitas Capital LLC acquired a new stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,290,187 shares of the company's stock, valued at approximately $4September 29, 2024 | marketbeat.comJean-Pierre Sommadossi Sells 33,941 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) StockSeptember 20, 2024 | insidertrades.comAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) Forecasted to Earn Q3 2024 Earnings of ($0.43) Per ShareAtea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) - Analysts at William Blair upped their Q3 2024 earnings per share (EPS) estimates for shares of Atea Pharmaceuticals in a research report issued to clients and investors on Monday, September 16th. William Blair analyst A. Hsieh now expects tSeptember 18, 2024 | marketbeat.comAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) Sees Large Growth in Short InterestAtea Pharmaceuticals, Inc. (NASDAQ:AVIR - Get Free Report) was the target of a large growth in short interest in August. As of August 31st, there was short interest totalling 2,830,000 shares, a growth of 13.7% from the August 15th total of 2,490,000 shares. Approximately 3.8% of the company's shares are short sold. Based on an average trading volume of 233,300 shares, the short-interest ratio is presently 12.1 days.September 15, 2024 | marketbeat.comAdobe, SelectQuote, Similarweb And Other Big Stocks Moving Lower In Friday's Pre-Market SessionSeptember 15, 2024 | msn.comAtea Pharmaceuticals, Inc.: Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19September 14, 2024 | finanznachrichten.deAtea Pharmaceuticals: Hold Rating Amidst Clinical Trial Setbacks and Future HepC FocusSeptember 14, 2024 | markets.businessinsider.comAtea Pharmaceuticals Shares Fall on Covid-19 Treatment Trial ResultSeptember 13, 2024 | marketwatch.comAtea Pharmaceuticals Trial of Covid-19 Treatment Bemnifosbuvir Fails to Meet Primary EndpointSeptember 13, 2024 | marketwatch.comAtea Pharma's Phase 3 SUNRISE-3 Study Of Bemnifosbuvir To Treat Covid-19 FailsSeptember 13, 2024 | markets.businessinsider.comAtea Pharmaceuticals' COVID-19 Treatment Flunks In Late-Stage Study, Blames 'Constantly Evolving' VirusSeptember 13, 2024 | finance.yahoo.comAtea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19September 13, 2024 | globenewswire.comAtea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir’s Metabolic Activation PathwayAugust 28, 2024 | finance.yahoo.comAtea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir's Metabolic Activation PathwayAugust 28, 2024 | globenewswire.comAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q2 2024 Earnings Call TranscriptAugust 14, 2024 | insidermonkey.comAVIR Jan 2025 5.000 putAugust 14, 2024 | ca.finance.yahoo.comMorgan Stanley Upgrades Atea Pharmaceuticals (AVIR)August 14, 2024 | msn.comAVIR Jan 2025 7.500 callAugust 13, 2024 | ca.finance.yahoo.comAtea rises after Morgan Stanley upgradeAugust 13, 2024 | msn.comAtea Pharmaceuticals (NASDAQ:AVIR) Upgraded by Morgan Stanley to Equal WeightMorgan Stanley raised Atea Pharmaceuticals from an "underweight" rating to an "equal weight" rating and raised their price target for the stock from $2.00 to $6.88 in a report on Tuesday.August 13, 2024 | marketbeat.comNVO Aug 2024 75.000 putAugust 13, 2024 | ca.finance.yahoo.comNVO Aug 2024 110.000 callAugust 13, 2024 | ca.finance.yahoo.comNVO Aug 2024 170.000 callAugust 13, 2024 | ca.finance.yahoo.comHold Rating on Atea Pharmaceuticals Amidst Competitive Landscape and Market UncertaintiesAugust 13, 2024 | markets.businessinsider.comWilliam Blair Weighs in on Atea Pharmaceuticals, Inc.'s Q3 2024 Earnings (NASDAQ:AVIR)Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) - Investment analysts at William Blair raised their Q3 2024 EPS estimates for Atea Pharmaceuticals in a report released on Wednesday, August 7th. William Blair analyst T. Lugo now expects that the company will earn ($0.45) per share for the qAugust 12, 2024 | marketbeat.comAtea Pharmaceuticals (NASDAQ:AVIR) Releases Earnings Results, Beats Expectations By $0.28 EPSAtea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) released its earnings results on Wednesday. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.28. During the same quarter in the previous year, the business earned ($0.34) EPS.August 8, 2024 | marketbeat.comAVIR Jan 2025 5.000 put (AVIR250117P00005000)August 8, 2024 | finance.yahoo.comAtea Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 8, 2024 | finance.yahoo.comAtea Pharmaceuticals (AVIR) Scheduled to Post Quarterly Earnings on WednesdayAtea Pharmaceuticals (NASDAQ:AVIR) will be releasing earnings after the market closes on Wednesday, August 7, Zacks reports.August 1, 2024 | marketbeat.comAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) Sees Significant Increase in Short InterestAtea Pharmaceuticals, Inc. (NASDAQ:AVIR - Get Free Report) was the recipient of a large growth in short interest in July. As of July 15th, there was short interest totalling 2,370,000 shares, a growth of 5.8% from the June 30th total of 2,240,000 shares. Based on an average trading volume of 261,100 shares, the days-to-cover ratio is currently 9.1 days. Currently, 3.2% of the shares of the stock are short sold.July 31, 2024 | marketbeat.comAtea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024July 31, 2024 | globenewswire.comAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) Short Interest UpdateAtea Pharmaceuticals, Inc. (NASDAQ:AVIR - Get Free Report) was the recipient of a significant increase in short interest in the month of June. As of June 30th, there was short interest totalling 2,240,000 shares, an increase of 5.2% from the June 15th total of 2,130,000 shares. Based on an average daily volume of 257,800 shares, the short-interest ratio is presently 8.7 days. Currently, 3.0% of the company's stock are short sold.July 17, 2024 | marketbeat.comAtea Pharmaceuticals, Inc. (NASDAQ:AVIR) Director Sells $61,228.56 in StockJune 25, 2024 | insidertrades.comAtea Pharmaceuticals to Present at the Jefferies Healthcare ConferenceMay 29, 2024 | globenewswire.comAtea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024May 22, 2024 | globenewswire.comQ2 2024 EPS Estimates for Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Lowered by AnalystAtea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) - Equities researchers at Leerink Partnrs lowered their Q2 2024 earnings per share estimates for shares of Atea Pharmaceuticals in a research report issued on Tuesday, May 14th. Leerink Partnrs analyst R. Ruiz now forecasts that the company wMay 17, 2024 | marketbeat.comResearch Analysts Set Expectations for Atea Pharmaceuticals, Inc.'s Q1 2025 Earnings (NASDAQ:AVIR)Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) - Equities research analysts at William Blair issued their Q1 2025 earnings estimates for Atea Pharmaceuticals in a report issued on Wednesday, May 15th. William Blair analyst T. Lugo anticipates that the company will post earnings of ($0.60)May 16, 2024 | marketbeat.com Get Atea Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AVIR and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s Back, but DC’s Coming for Your Money! (Ad)Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back… Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov AVIR Media Mentions By Week AVIR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AVIR News Sentiment▼0.720.55▲Average Medical News Sentiment AVIR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AVIR Articles This Week▼61▲AVIR Articles Average Week Get Atea Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AVIR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Inovio Pharmaceuticals News Bicycle Therapeutics News ArriVent BioPharma News Ardelyx News Phibro Animal Health News Immatics News Collegium Pharmaceutical News CARGO Therapeutics News Prothena News Cullinan Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AVIR) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atea Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atea Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
